Nasdaq:HIT
Health In Tech, Inc.
A Nasdaq-listed health technology firm delivering scalable digital solutions to improve clinical workflows and patient outcomes for healthcare providers.
Key Metrics
Investment Thesis
Bull Case
HIT offers an attractive entry point for growth investors seeking exposure to the expanding digital health market with a robust gross margin structure of roughly 79%. The company's ability to convert a significant portion of revenue into operating cash flow, even amidst high administrative costs, demonstrates operational efficiency and product demand. With $7.8M in cash and equivalents against manageable long-term liabilities, the balance sheet provides sufficient runway for R&D investment and market penetration without immediate dilution pressure.
Bear Case
Potential buyers should be wary of the significant retained earnings deficit of $3.9M, which suggests the company has historically struggled to retain profits or has funded aggressive growth strategies at the expense of accumulation. Operating expenses of $14.4M are substantial relative to a $19.5M revenue base, creating a thin operating profit margin that leaves little room for error in pricing power or cost control. The heavy reliance on non-cash adjustments like share-based compensation ($0.47M) inflates reported earnings without delivering corresponding cash flow benefits.
About Health In Tech, Inc.
Health In Tech Inc. (HIT) is a technology-focused healthcare company leveraging digital solutions to optimize patient care and operational efficiency within the medical sector. The company serves hospitals, clinics, and private practices with software platforms designed to streamline administrative workflows and enhance data management. Key revenue streams include licensing proprietary health-tech applications and providing subscription-based services that integrate seamlessly with existing electronic health record systems.
Analysis
Management Discussion
Management successfully generated $2.2M in operating cash flow against $19.5M in revenue, though this figure is bolstered by $3.9M in non-cash adjustments including share-based compensation of nearly half a million dollars. The company reported a net profit of $0.7M while maintaining a healthy current ratio derived from $10.8M in current assets versus $2.1M in current liabilities, signaling strong short-term liquidity despite a retained earnings deficit of $3.9M. Strategic investments totaling $836k in investing activities were partially offset by $4.1M raised through financing and share issuances to fund expansion.
Industry Overview
The global health technology sector is experiencing rapid expansion driven by the shift toward value-based care and the need for interoperable digital infrastructure across hospital networks. Companies in this space are increasingly competing on data security, seamless integration capabilities, and the ability to demonstrate measurable improvements in patient outcomes. Regulatory headwinds regarding data privacy continue to shape the competitive landscape, requiring firms to invest heavily in compliance while scaling their user bases.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2024 |
|---|---|
| Revenue | $19.5M |
| Cost of Revenue | $4.1M |
| Gross Profit | $15.4M |
| Operating Expenses | $14.4M |
| Operating Income | $989.9K |
| R&D | $2.8M |
| G&A | $8.5M |
| Marketing | $3.2M |
| Stock-Based Comp | $468.5K |
| D&A | $541.1K |
| Other OpEx | $0 |
| Non-Operating Income | $-100.9K |
| Interest Income | $64.0K |
| Pre-Tax Income | $889.0K |
| Income Tax | $218.5K |
| Continuing Ops | $670.5K |
| Discontinued Ops | $0 |
| Net Income | $670.5K |
| Minority Interest | $0 |
| Net to Common | $670.5K |
| Metric | 2024 |
|---|---|
| Current Assets | $10.8M |
| Cash & Equivalents | $7.8M |
| Accounts Receivable | $1.6M |
| Prepaid Expenses | $787.2K |
| Other Current Assets | $500.3K |
| Long-Term Assets | $5.0M |
| Operating Leases | $206.3K |
| Other LT Assets | $4.8M |
| Total Assets | $15.8M |
| Current Liabilities | $2.1M |
| Current Leases | $66.9K |
| Other Current Liab | $2.1M |
| Long-Term Liabilities | $468.5K |
| LT Operating Leases | $139.8K |
| Other LT Liab | $328.7K |
| Total Liabilities | $2.6M |
| Shareholders' Equity | $13.2M |
| Paid-In Capital | $9.2M |
| Retained Earnings | $3.9M |
| Total L&E | $15.8M |
| Metric | 2024 |
|---|---|
| Net Income (CFO) | $670.5K |
| Non-Cash Adjustments | $3.9M |
| Working Capital Changes | $-2.4M |
| Cash from Operations | $2.2M |
| Cash from Investing | $-836.8K |
| Cash from Financing | $4.1M |
| FX Effect | $0 |
| Net Change in Cash | $5.4M |
| Beginning Cash | $2.4M |
| Ending Cash | $7.8M |
Frequently Asked Questions
How does Health In Tech, Inc. make money?
The company's revenue is primarily driven by software licensing fees, recurring SaaS subscriptions for its core platform, professional services for implementation and customization, and data analytics services that provide actionable insights for hospital administrators.
What are the main risks for HIT?
As a capital-light but asset-light growth company, HIT faces risks from rapid technological obsolescence in the fast-moving health-tech sector where customer preferences shift quickly. The company's reliance on a concentrated client base within specific geographic markets could expose it to regulatory changes or payer reimbursement cuts that impact overall spending. High general and administrative expenses relative to revenue suggest potential margin compression if sales growth slows, while cash flow from operations being lower than net income indicates significant non-cash adjustments like share-based compensation.
What is HIT's competitive advantage?
HIT differentiates itself through a proprietary algorithm engine that minimizes integration time with legacy healthcare systems, reducing deployment costs for clients. The firm maintains a high gross margin profile of approximately 79%, indicating strong product stickiness and low marginal costs. Additionally, the company has successfully scaled its recurring revenue base to provide predictable cash flows essential for long-term valuation.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.